"10.1371_journal.pone.0028973","plos one","2011-12-14T00:00:00Z","Mohammad Atefi; Erika von Euw; Narsis Attar; Charles Ng; Connie Chu; Deliang Guo; Ramin Nazarian; Bartosz Chmielowski; John A Glaspy; Begonya Comin-Anduix; Paul S Mischel; Roger S Lo; Antoni Ribas","Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, California, United States of America; Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California, United States of America; Department of Medicine, Division of Dermatology, University of California Los Angeles, Los Angeles, California, United States of America; Department of Surgery, Division of Surgical Oncology, University of California Los Angeles, Los Angeles, California, United States of America; Jonsson Comprehensive Cancer Center at University of California Los Angeles, Los Angeles, California, United States of America","Conceived and designed the experiments: MA EvE BC JAG BC-A PSM RSL AR. Performed the experiments: MA EvE NA CN CC DG RN BC-A. Analyzed the data: RN BC JAG BC-A PSM RSL AR. Contributed reagents/materials/analysis tools: MA EvE NA CN DG BC JAG BC-A PSM RSL AR. Wrote the manuscript: MA EvE RSL AR.","The authors have read the journals policy and have the following conflicts. Antoni Ribas has has served as a consultant and has received honoraria from Hoffman-La Roche and Plexxikon, the makers of vemurafenib. This does not alter the authors adherence to all the PLoS ONE policies of the manuscript.","2011","12","Mohammad Atefi","MA",13,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
